JNJ Johnson & Johnson Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
05:12
Sep 01
Sep 01
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings.
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings as a watchlist, not an explicit position.
LOW
23:42
Aug 27
Aug 27
Solid healthcare stock for portfolio diversification.
Johnson & Johnson is a solid healthcare addition to a portfolio that is overly concentrated in tech stocks like Apple and Nvidia.
MED
12:31
Aug 25
Aug 25
Author confirms ongoing ownership of QSR and JNJ in response to a question about still holding.
Author confirms ongoing ownership of QSR and JNJ in response to a question about still holding both positions.
22:33
Aug 24
Aug 24
The FDA approved Johnson & Johnson's Imavvy as the first-ever treatment for warm autoimmune.
The FDA approved Johnson & Johnson's Imavvy as the first-ever treatment for warm autoimmune hemolytic anemia in patients aged 12 and older, marking a landmark regulatory milestone.
17:46
Aug 18
Aug 18
JNJ survived severe litigation with fines
Notes JNJ survived severe litigation with fines, used as a comparison for Meta's legal issues.
LOW
17:45
Aug 18
Aug 18
Author contrasts JNJ's legal settlement with META's algorithmic criticism.
Author contrasts JNJ's legal settlement with META's algorithmic criticism, suggesting META will recover to all-time highs without taking a position.
LOW
13:00
Aug 17
Aug 17
Highlights largest single-fund new positions.
Highlights largest single-fund new positions for Q2 2026, no directional view.
MED
11:27
Aug 15
Aug 15
The author is compiling a research thread of user-recommended non-AI tickers.
The author is compiling a research thread of user-recommended non-AI tickers, listing them as a factual watchlist
LOW
13:07
Aug 08
Aug 08
The tweet lists large-cap pharma companies with high short interest.
The tweet lists large-cap pharma companies with high short interest, citing a Financial Times article, but offers no personal position or directional call.
LOW
01:14
Aug 08
Aug 08
A regulatory filing shows that Duato sold 41,957 Johnson & Johnson shares at an average price.
A regulatory filing shows that Duato sold 41,957 Johnson & Johnson shares at an average price of $258.06 per share.
01:13
Aug 08
Aug 08
Johnson & Johnson executive Duato discloses a share sale of 1.69 million dollars at an average.
Johnson & Johnson executive Duato discloses a share sale of 1.69 million dollars at an average price of 258.74 per share.
00:23
Aug 07
Aug 07
Buy Eli Lilly and JNJ on weakness
Tech has had such a run that portfolio managers want exposure to other innovative sectors. Eli Lilly and Johnson & Johnson are non-tech tech stocks with strong innovation. Both just reported terrific quarters and deserve to be bought on any weakness.
MED
23:45
Aug 06
Aug 06
Healthcare innovation catches tech rotation
After tech's massive run, portfolio managers are seeking innovation in other sectors. Healthcare stocks like Eli Lilly, Johnson & Johnson, Amgen, and Moderna are non-tech tech stocks with strong quarters and pipelines, representing a rotation opportunity.
MED
10:14
Aug 03
Aug 03
Goldman Sachs refreshes its U.S. Conviction List by adding six stocks including Applied.
Goldman Sachs refreshes its U.S. Conviction List by adding six stocks including Applied Materials and Delta while removing four others including Broadcom and ServiceNow.
10:13
Aug 03
Aug 03
Goldman Sachs adds six stocks to its US Conviction Buy list while removing four others.
Goldman Sachs adds six stocks to its US Conviction Buy list while removing four others, reflecting a routine portfolio rebalancing with no explicit price targets or directional commentary from named analysts.
12:00
Aug 02
Aug 02
Differentiated Ottava drives J&J's robotic surgery growth.
Johnson & Johnson's Ottava robotic surgery platform is a differentiated, category-defining innovation with arms integrated into the surgical table, entering a market with only 8% global penetration and fast adoption. J&J expects Ottava to become material toward the end of the decade, supported by upcoming FDA submissions for specific procedures and expansion into key markets like Japan and Europe. The company believes the architecture gives it a competitive edge even though it is not first to market.
HIGH
23:15
Jul 31
Jul 31
JNJ has AAA balance sheet for kids.
Johnson & Johnson has a AAA-rated balance sheet, making it the safest stock to buy for young children as a long-term investment, alongside best-of-breed tech names.
MED
23:00
Jul 31
Jul 31
J&J's unique robotic surgery poised for growth
Johnson & Johnson's Ottava robotic surgery platform has a differentiated architecture (arms integrated into the table) that reduces operating room friction, while the robotic surgery market has only 8% penetration and is fast-growing. J&J expects its robotics business to become materially significant towards the end of the decade and aims to become a leader in surgical robotics.
HIGH
00:50
Jul 31
Jul 31
Sector rotation out of biotech into semis.
A sector rotation is underway out of defensive havens like US biotech and back into beaten-down semiconductors. During the recent semiconductor sell-off, capital fled to safer areas like biotech, pushing stocks like Eli Lilly to new highs. Now, with signs of a bottom in tech, that money is flowing back, causing profit-taking in biotech. This is a short-term tactical call to avoid the biotech sector.
MED
00:02
Jul 30
Jul 30
Johnson & Johnson's strategic agreement to acquire Sail Biomedicines for $2.58 billion is.
Johnson & Johnson's strategic agreement to acquire Sail Biomedicines for $2.58 billion is reported as a factual deal announcement, not a personal position or forward call.
LOW
22:20
Jul 29
Jul 29
Johnson & Johnson announced a collaboration with privately held Sail Biomedicines to develop.
Johnson & Johnson announced a collaboration with privately held Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases, according to a company statement.
21:29
Jul 29
Jul 29
Johnson & Johnson enters strategic agreements with Sail Biomedicines including an exclusive.
Johnson & Johnson enters strategic agreements with Sail Biomedicines including an exclusive option to acquire the company for $2.58 billion and an equity investment with total initial payments of $785 million.
21:29
Jul 29
Jul 29
Johnson & Johnson reports in a SEC filing that adjusted operational EPS and adjusted EPS are.
Johnson & Johnson reports in a SEC filing that adjusted operational EPS and adjusted EPS are expected to decrease by $0.64 in 2026 and by $1.36 in 2027.
21:29
Jul 29
Jul 29
Johnson & Johnson forecasts fiscal year 2026 adjusted earnings per share of $10.96 to $11.11.
Johnson & Johnson forecasts fiscal year 2026 adjusted earnings per share of $10.96 to $11.11, below the IBES consensus estimate of $11.69.
19:59
Jul 29
Jul 29
Author discloses current long position in JNJ with stops at breakeven or better.
Author discloses current long position in JNJ with stops at breakeven or better; position still acting relatively well per follow-up.
MED
19:59
Jul 29
Jul 29
Author discloses active long position in JNJ with breakeven-or-better stop.
Author discloses active long position in JNJ with breakeven-or-better stop; position acting relatively well and being held.
MED
18:42
Jul 29
Jul 29
Author speculates on JNJ's potential M&A interest in KRYS and ABVX based on plane tracking.
Author speculates on JNJ's potential M&A interest in KRYS and ABVX based on plane tracking, but frames it as purely speculative with no position.
LOW
18:24
Jul 29
Jul 29
Reports JNJ office/plan relocation from Pittsburgh to Boston; factual observation only.
LOW
00:56
Jul 29
Jul 29
Johnson & Johnson agrees to pay up to $5.5 billion to settle talc lawsuits.
Johnson & Johnson agrees to pay up to $5.5 billion to settle talc lawsuits, a factual legal development with no expressed trading position.
LOW
18:18
Jul 28
Jul 28
Johnson & Johnson's $5.5B talc settlement is a neutral development given the company's strong.
Johnson & Johnson's $5.5B talc settlement is a neutral development given the company's strong financials, with Seeking Alpha maintaining a HOLD rating.
About JNJ Analyst Coverage
Buzzberg tracks JNJ (Johnson & Johnson) across 27 sources. 37 bullish vs 0 bearish calls from 41 analysts. Sentiment: predominantly bullish (34%). 110 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: asklivermore, Jim Cramer, FirstSquawk.